Calidi Biotherapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.688 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 2.54M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Details
| Name | Calidi Biotherapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 29 |
| Founded | 2014 |
| Ceo | Eric Poma |
| Country | United States |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US3207035078 |
| Cusip | 320703507 |
| Cik | 1855485 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Eric E. Poma Ph.D. | Chief Executive Officer and Director |
| Andrew C. Jackson | Chief Financial Officer and Corporate Secretary |
| Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D. | Head of Technical Operations and Chief Scientific Officer |
| Dr. Guy Travis Clifton M.D. | Chief Medical Officer |
Contact
| Address | 4475 Executive Drive, Suite 200, San Diego, California 92121, United States |
| Phone | 858 794 9600 |
| Website | https://www.calidibio.com |